NCT Number: NCT00551304
Native Kidney Denervation in Patients With End Stage Renal Disease
To investigate the utility of renal denervation in the treatment of patients with End Stage Renal Disease (ESRD).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
The Alfred Hospital, Melbourne, Victoria, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- adult >= 18 years of age
- end stage renal disease, undergoing concurrent dialysis treatment
- poorly controlled blood pressure on at least 2 antihypertensive drugs
- agrees to have the study procedure(s) performed and additional procedures and evaluations, including interventions and follow up visits
- competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion criteria
- renal arterial abnormalities
- myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within six (6) months
- hemodynamically significant valvular heart disease
- implantable cardioverter defibrillator (ICD) or pacemaker
- respiratory support.
- pregnant, nursing or planning to be pregnant
- other
Treatment and study plan
Primary outcomes
-
To provide confirmation that renal denervation in ESRD patients is safe and feasible.
Secondary outcomes
-
To provide evidence of denervation, indication of physiologic response, and assess device performance.
Sponsors and collaborators
Lead sponsor
Medtronic Vascular
Industry
Registry information
Important dates
- Study start
- 2007
- First posted
- Oct 30, 2007
- Registry last updated
- Nov 6, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Association of Middle Molecules Clearance With HDF Volume
NCT06515899
Chronic Disease, Disease Attributes
Stevenage, Hertfordshire, United Kingdom
View Trial DetailsVIRTUUS Children's Study
NCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsSafety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
NCT04817774
Chronic Disease, Disease Attributes
Leuven, Belgium
View Trial DetailsCommunication During Hospitalization About Resuscitation Trial
NCT02984124
Chronic Disease, Disease Attributes
Chapel Hill, North Carolina, United States
View Trial Details